Connect with us

Health

Novak Djokovic denied entry to Australia, has visa canceled on failing COVID-19 norms

Novak Djokovic’s chance to play for a 10th Australian Open title was thrown into limbo on Thursday when the country denied him entry and canceled his visa because he failed to meet the requirements for an exemption to COVID-19 vaccination rules.

The top-ranked Djokovic announced on social media Tuesday that he had “exemption permission” and he landed in Australia late Wednesday with a medical exemption from the Victoria state government that was expected to shield him from the strict vaccination regulations in place for this year’s first major tennis tournament.

Read the latest updates in our dedicated coronavirus section.

But national border authorities didn’t accept the exemption, with the Australian Border Force issuing a statement saying Djokovic failed to meet entry requirements.

For the latest headlines, follow our Google News channel online or via the app.

“The rule is very clear,” Prime Minister Scott Morrison told a news conference. “You need to have a medical exemption. He didn’t have a valid medical exemption. We make the call at the border, and that’s where it’s enforced.”

Health Minister Greg Hunt said the visa cancellation followed a review of Djokovic’s medical exemption by border officials who looked “at the integrity and the evidence behind it.”

He said Djokovic was free to appeal the decision, “but if a visa is canceled, somebody will have to leave the country.”

The president of Djokovic’s native Serbia blasted the “harassment” of the star, who was detained overnight at Melbourne Tullamarine Airport. The 20-time major winner had to wait more than eight hours at the airport to find out if he would be allowed into the country. He was later moved to a secure hotel near downtown Melbourne.

The Australian Broadcasting Corp. and other local media reported that action had been launched in the Federal Court against the cancellation of Djokovic’s visa.
Quarantine-free access wouldn’t have been an issue if Djokovic had been able to prove he was fully vaccinated for the coronavirus. Instead he applied for a medical exemption, a route that only became an option in recent months after Victoria state backed away from a full no-vaccination, no-play policy.

Questions have been raised about the approval of the exemption.

The Sydney Morning Herald published letters sent late last year from the Department of Health and Health Minister Greg Hunt to Tennis Australia which indicated that Djokovic, at that time, didn’t meet the standard for quarantine-free entry.

Responding to questions about confusion over the differing state and federal requirements, Morrison said it was up to individual travelers to have correct documentation on arrival.

The prime minister rejected the suggestion that Djokovic was being singled out, but he acknowledged that other players may be in Australia on the same type of medical exemption.

“One of the things the Border Force does is they act on intelligence to direct their attention to potential arrivals,” he said. “When you get people making public statements about what they say they have, and they’re going to do, they draw significant attention to themselves.”

Anyone who does that, he said, “whether they’re a celebrity, a politician, a tennis player . . . they can expect to be asked questions more than others before you come.”

The medical exemptions, vetted by two independent panels of experts and based on information supplied anonymously by players and taken on face value, had been designed to allow Djokovic to play in the Australian Open, regardless of his vaccination status.

He has spoken out against vaccines in the past and has steadfastly refused to acknowledge whether he received any shots against the coronavirus.

His father, Srdjan Djokovic, told the B92 internet portal that his son was held at the airport “in a room which no one can enter” and guarded by two police officers.

Serbian President Aleksandar Vucic said on Instagram that he spoke to Djokovic while he was being held at the airport. He said Serbian authorities were taking measures “so the harassment of the best tennis player in the world be stopped in the shortest possible time.”

Djokovic’s revelation on social media that he was heading to Australia to seeking a record 21st major title instantly became a hot political topic. Many Australians who have struggled to obtain sparsely available and often expensive rapid antigen tests, or who have been forced into isolation, perceived a double standard in the exemption allowance for Djokovic.

Critics questioned what grounds he could have for the exemption, and backers argued that he has a right to privacy and freedom of choice.

Tension is growing amid another surge of COVID-19. The state recorded six deaths and 21,997 new cases on Thursday, the biggest daily jump in cases in Victoria since the pandemic began.

Australian Open tournament director Craig Tiley on Wednesday defended the “completely legitimate application and process” and insisted there was no special treatment for Djokovic.

The Victoria government has mandated that only fully vaccinated players, staff members, fans, and officials can enter Melbourne Park when the tournament begins Jan. 17.

Only 26 people connected with the tournament applied for a medical exemption and, Tiley said, only a “handful” were granted. None of those players have been publicly identified.

Among the acceptable reasons for an exemption are acute major medical conditions, serious adverse reaction to a previous dose of COVID-19 vaccine or evidence of a COVID-19 infection within the previous six months.
Djokovic tested positive for the coronavirus in June 2020 after he played in a series of exhibition matches that he organized in Serbia and Croatia without social distancing amid the pandemic.

Concerns about the visa status heightened on Wednesday when Morrison — after initially saying it was a matter for the Victoria government — said if the evidence to support Djokovic’s exemption application was deemed insufficient, "then he won’t be treated any different to anyone else, and he’ll be on the next plane home.”

Home Affairs Minister Karen Andrews said while the state government and tennis organizers “may permit a non-vaccinated player to compete in the Australian Open, it is the Commonwealth government that will enforce our requirements at the Australian border.”

Read more:

Tennis star Novak Djokovic opposes compulsory coronavirus vaccination

Australia suffers record COVID-19 cases, straining businesses and supply chains

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

Children’s Hospital Los Angeles Named Among Top 10 Children’s Hospitals in the United States 16 Years in a Row

As a leader in pediatric academic medicine, Children’s Hospital Los Angeles (CHLA) has continued to fulfill its mission by making discoveries and advances to enhance health and save lives. Today, Children’s
Hospital Los Angeles was recognized among the top 10 pediatric hospitals in the United
States, according to U.S. News & World Report, which has announced the 2024-25
edition of its annual Best Children’s Hospitals rankings.
The privilege of earning a place on U.S. News Honor Roll of Best Children’s
Hospitals has been conferred upon CHLA 16 years and counting, since the magazine
created the list. Additionally, CHLA retained its No. 1 children’s hospital ranking in U.S.
News’ separate regional survey of Pacific Rim pediatric hospitals, tying with two others
in the region. Children’s Hospital Los Angeles also tied for No. 1 in California and is the
No. 1 pediatric provider in Los Angeles. For the 2024-25 survey, U.S. News did not
publish ordinal rankings for the 10 hospitals that made the Honor Roll. All 10 are
considered equally top tier.
“Being recognized as one of the top children’s hospitals in the country demonstrates our
unwavering commitment and excellence in pediatric healthcare,” says CHLA President
and Chief Executive Officer Paul S. Viviano. “We are committed to enhancing health,
saving lives and providing the best care for children, teens, young adults and the
families we serve. Our dedicated team of doctors, nurses, and staff, all contribute to
helping us put our patients first and are the reason this achievement continues to be
possible.”
U.S. News & World Report also ranked hospitals in 11 individual subspecialties, and
CHLA was ranked in all of these. CHLA earned top-10 recognition in five of the
specialties: Cancer (6), Endocrinology (6), Gastroenterology & GI
Surgery (6), Orthopedics (4) and Urology (4). In all, CHLA earned national recognition
in all 11 specialty areas, including: Cardiology (12), Nephrology
(16), Neurology & Neurosurgery (15), Neonatology (21) and Pulmonology (11).
Children’s Hospital Los Angeles was also honored in U.S. News & World Report’s
newest category—Pediatric and Adolescent Behavioral Health—which was added in
response to the national mental health crisis affecting children, adolescents and young
adults. For this first year, the publication identified CHLA among a group of 50 pediatric

hospitals providing the highest quality, compassionate care for youth coping with
behavioral and emotional challenges. CHLA’s Behavioral Health Institute provides
seamless care of Psychiatry, Developmental-Behavioral Pediatrics, Psychology, and
Social Work services, including for specific conditions such as autism spectrum disorder
and other developmental disabilities.
“Being ranked as one of the nation’s top hospitals in the country reflects our ability to
offer and provide specialized pediatric services, including world class care for complex
cases – rare and chronic conditions treated by multi-disciplinarian teams of pediatric
clinicians. This ability to care for these unique children is what sets CHLA apart from
other hospitals,” says CHLA Chief Medical Officer James Stein, MD, MSc. “At CHLA
we deliver more pediatric care for patients with complex conditions than any other
hospital in California. We are constantly advancing our practices and research to
provide solutions that continue to save lives.”
Children’s Hospital Los Angeles has more than 8,000 team members—including nearly
1,000 pediatric specialist physicians. The hospital performs nearly 16,000 surgeries and
conducts more than 723,000 patient visits each year. As a pediatric academic medical
center, CHLA delivers world-class medical care; conducts groundbreaking scientific
research to develop new treatments and new cures for childhood diseases at The
Saban Research Institute of CHLA; and operates one of the largest pediatric training
programs in the country for physicians, nurses and other specialists.
CHLA is one of the nation’s premier pediatric institutions with services and outcomes for
rare and complex conditions among the best in the world. It has treated patients from
more than 90 countries and has a dedicated Center for Global Health to support the
unique needs of international patients and families traveling to CHLA for specialty and
complex care needs. International patients and families can contact the Center for
Global Health at internationalpatientreferrals@chla.usc.edu.
“Our Center for Global Health supports the unique needs of international patients with a
single point-of-contact to make it easy for them and their families to access and
navigate all aspects of care,” said Yadira Torres, Executive Director of the Global Health
Program at CHLA. “We also make it a priority to be culturally diverse, offering services
in over 34 languages, so families can easily and effectively communicate with our
doctors, nurses and medical staff.”
Each year, U.S. News & World Report and research firm RTI International develop the
Best Children’s Hospital list. For 2024-25, The Best Hospitals specialty rankings
assessed nearly 200 pediatric hospitals—including freestanding institutions like CHLA,
children’s hospitals that are part of a larger health system, and specialty pediatric
centers. Each was scored across hundreds of benchmarks, including quality and safety
performance; patient outcomes; peer recognition; research; technology; commitment to
care that is diverse, equitable and inclusive; certifications; third-party awards; and other
data points provided by each hospital.

Continue Reading

Health

Tamkeen’s support for “Amana Healthcare” will provide hundreds of job opportunities for local talent in the healthcare sector

– Collaboration will generate job opportunities for local talent and support the growth of
Bahrain’s healthcare sector
– Recruitment Day on 12 October in Manama with vacancies for doctors, nurses, physical
therapists, nutritionists, and administrative staff.
– Amana Healthcare’s new facility in Al Jasra will replicate the successful patient care
model of M42’s Amana Healthcare in the UA

The Labour Fund “Tamkeen”has announced its collaboration with Amana Healthcare to attract top talent to Bahrain to deliver specialized rehabilitation and long-term care services for individuals with complex medical needs. This collaboration will create promising job opportunities for Bahrainis and strengthen
the Kingdom’s position as a growing hub for specialized healthcare services.
As part of this initiative, a Recruitment Day will take place on 12 October 2024 in Manama to
recruit the Kingdom’s most skilled local professionals to join Amana Healthcare’s team.
Qualified candidates may register online by 8 October at amanahealthcarebh.com for various
positions including doctors, nurses, physical therapists, nutritionists, and administrative staff.
Tamkeen’s support for Amana Healthcare is aligned with its strategic priorities focused on
economic impact under three pillars: increasing economic participation through employment,
career development opportunities for local talent in the private sector, and supporting private
sector enterprises to be the engine of economic growth.
Commenting on the collaboration, Her Excellency Ms. Maha Abdulhameed Mofeez, Chief
Executive of Tamkeen, said: “Tamkeen’s support for Amana Healthcare is a continuation of our
ongoing efforts to support the growing healthcare sector, which currently employs more than
15,800 Bahrainis across various roles and specialties. We are proud to collaborate with Amana
Healthcare for its prominent role in providing integrated services and improving the quality of
healthcare in line with the highest global standards.”

Amana Healthcare, part of the M42 group, an Abu Dhabi-based tech-enabled global health
powerhouse, will launch the new specialized facility in partnership with Mumtalakat in 2025.
Amana Healthcare features state-of-the-art facilities and aims to reduce the pressure on
hospitals caused by long-term medical patients.
Dr. Mohamed AlSaati, Acting CEO of M42 Bahrain and CEO of Amana Healthcare in Bahrain
highlighted that bringing M42’s world-class tried and tested model for complex long-term and
post-acute rehabilitation services to Bahrain for the first time, will positively impact local
communities and create highly skilled jobs for Bahrainis. He said: “We’re committed to
enhancing and transforming the healthcare infrastructure in Bahrain by hiring, training, and
developing the very best Bahraini talent, including nurses, doctors, technicians, and support
staff.”
It is worth mentioning that Tamkeen has previously announced the launch of the largest
support bundle to train and employ national talent in the healthcare sector in collaboration
with the Supreme Council of Health, aimed at developing and training more than 700 Bahraini
professionals in the healthcare sector. This is part of Tamkeen’s mandate to make Bahrainis the
first choice for employment while also supporting private sector enterprises as the main driver
of economic growth in the kingdom.

 

Continue Reading

Health

Boehringer Ingelheim Launches Broadest Spectrum Parasiticide for Cats in the UAE

– The solution combines three medications delivering the broadest spectrum of protection
against internal and external parasites in cats.
– The solution is safe for cats from eight weeks of age in addition to pregnant and lactating
cats.
– The solution aims to ensure convenience for veterinarians, while ensuring cat owner
compliance and broad-spectrum protection for cats against parasite

Boehringer Ingelheim has launched a breakthrough monthly parasiticide solution for cats in the UAE, to ensure convenient and comprehensive protection for cats and cat owners.
The solution combines esafoxolaner for fleas and ticks, and eprinomectin and praziquantel for internal
parasites, delivering a broad-spectrum of protection against fleas, ticks, mites, worms, and other
parasites. The solution is safe for cats from eight weeks of age in addition to pregnant and lactating cats
and provides a one and done solution, ensuring convenience for veterinarians, cat owners and cats alike.
During the launch event, which took place on 30 September in the presence of over 100 veterinarians
from the UAE and beyond, Dr. Remo Lobetti, President of the European College of Veterinary
Internal Medicine and a renowned expert in small animal medicine, spoke about the significant health
risks that parasites pose to cats. He emphasized the importance of comprehensive protection, stating,
“Feline parasites can cause a variety of health issues, ranging from mild skin irritations to serious
diseases that affect multiple organs. While fleas are the most common parasite in cats, there are many
other internal parasites that go unnoticed but pose severe health risks. The new solution by Boehringer
Ingelheim is a groundbreaking solution addressing not just the visible signs but also the hidden threats,
offering cats all-round protection. It’s an innovative step forward in parasite control, providing much
needed peace of mind for veterinarians and cat owners.”
Gurkan Ulusoy, Head of Animal Health, Near East and UAE, at Boehringer Ingelheim, said,
“Contrary to popular belief, parasites are not limited to cats allowed outdoors. They can be found in dirt,
indoor and outdoor plants, shoes, and other animals. One of the main challenges in treating cats,
particularly here in the UAE, is ensuring that the treatment process is stress-free and convenient for both
pets and time-pressed owners. With the hot climate in the region, cats face especially high risk exposure
to a range of parasites year-round, not just during specific seasons. Boehringer Ingelheim has addressed
these concerns by offering a topical application that is easy to administer and provides comprehensive
protection. The convenience of the solution has the potential to create better compliance from pet owners,
ensuring domesticated cats remain protected”
The new solution by Boehringer Ingelheim is available by veterinarian prescription in the UAE, providing a
trusted solution for all cat owners to protect their pets against parasites. With its advanced formula and
convenient administration, the product represents a significant advancement in feline healthcare. Cat
owners are encouraged to consult their trusted veterinarians for more information on the various parasites
and their treatment.
The launch of the new solution is testament to Boehringer Ingelheim’s commitment to animal health
through detection, prevention, and treatment and adds to the company’s wide-ranging animal health
portfolio containing some of the most respected and widely used vaccines, parasiticides and therapeutics products. Over the past several decades, the global pharmaceutical leader has transformed the lives of animals and the people who care for them to help ensure no animal suffers from a preventable disease.

 

Continue Reading

Trending